Skip to main content
Medical information Clinical review pending

Cytogenetics

Immunohistochemistry AMACR Test

The Immunohistochemistry AMACR Test helps diagnose specific cancers, particularly prostate cancer, by detecting the Alpha-methylacyl-CoA racemase (AMACR) protein in tissue samples. This aids in accurate cancer classification and treatment planning.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Tumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block.
Results
Confirm with the laboratory before booking. Sample daily by 6 PM; report block: 5 days. Tissue biopsy: 5 days. Tissue large complex: 7 days.
Preparation
Ensure the sample is shipped at room temperature. Provide a copy of the Histopathology report, the site of biopsy, and relevant clinical history.
Test priceKSh 6,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Immunohistochemistry AMACR Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Diagnosis of prostate cancer
  • ✓Differentiation between benign and malignant prostate tissue
  • ✓Characterization of certain tumors
  • ✓Evaluation of patients with symptoms suggestive of prostate cancer
  • ✓Assessment of individuals with risk factors for prostate cancer
02

In plain language

What this test helps you understand

Aids in the diagnosis and classification of certain cancers, particularly prostate cancer, by detecting the presence of the AMACR protein in tissue samples.
The Immunohistochemistry AMACR Test is a specialized diagnostic tool used primarily in oncology. It plays a critical role in identifying and characterizing cancerous tissues, specifically aiding in the diagnosis of prostate cancer. By detecting the presence of Alpha-methylacyl-CoA racemase (AMACR) in tumor samples, healthcare providers can make more informed decisions regarding patient treatment plans.

This test measures the expression of AMACR, an enzyme often overexpressed in malignant tissues compared to benign ones. The presence of AMACR can help differentiate between cancerous and non-cancerous cells, providing vital information for accurate diagnosis.

This test is recommended for individuals with symptoms suggestive of prostate cancer, such as difficulty urinating or pelvic discomfort, or those with risk factors like age over 50 or a family history of the disease.

Taking this test offers benefits including accurate cancer diagnosis, distinguishing between benign and malignant tissues, and facilitating personalized treatment strategies. Results will be interpreted by your oncologist. A positive result typically indicates the presence of cancerous cells, while a negative result suggests the absence of malignancy. Discuss your results with your healthcare provider for a full understanding.

To conduct the test, tumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block must be submitted. Ship the sample at room temperature and provide a copy of the Histopathology report, biopsy site, and relevant clinical history.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationEnsure the sample is shipped at room temperature. Provide a copy of the Histopathology report, the site of biopsy, and relevant clinical history.
SampleTumor tissue in 10% Formal-saline or Formalin fixed paraffin embedded block.
MethodologyImmunohistochemistry (IHC) using antibodies specific to AMACR.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test is an aid to diagnosis and should be interpreted in conjunction with clinical findings and other diagnostic tests. A positive result does not definitively confirm cancer, and a negative result does not rule it out. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

AMACR stands for Alpha-methylacyl-CoA racemase. It is an enzyme that is often found in higher amounts in certain types of cancer cells, particularly prostate cancer cells, compared to normal cells.
This test is primarily used to help diagnose prostate cancer by detecting the AMACR protein in tissue samples obtained from a biopsy.
A tissue sample, typically from a biopsy, preserved in formalin or as a paraffin-embedded block, is required for this test.
Turnaround time varies depending on the sample type and complexity. Please confirm the specific turnaround time with the laboratory before booking.
Your doctor, typically an oncologist or pathologist, will interpret the results of the Immunohistochemistry AMACR Test in the context of your overall health and other diagnostic information.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp